Influence of Neoadjuvant Therapy with Epirubicin and Docetaxel on the Expression of HER2/neu in Patients with Breast Cancer

被引：0
|
作者：
Susanne Taucher
Margaretha Rudas
Robert M. Mader
Michael Gnant
Emanuel Sporn
Peter Dubsky
Sebastian Roka
Thomas Bachleitner
Florian Fitzal
Daniela Kandioler
Catharina Wenzel
Günther G. Steger
Martina Mittlböck
Raimund Jakesz
机构：
[1] Vienna University Medical School,Department of Surgery
[2] Vienna University Medical School,Department of Pathology
[3] Vienna University Medical School,undefined
来源：
Breast Cancer Research and Treatment | 2003年 / 82卷
关键词：
breast cancer; core needle biopsy; docetaxel; epirubicin; FISH; HER2/; immunohistochemistry; preoperative treatment; trastuzumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background. In primary breast cancer, the expression levels of biological markers relevant to the progression of the disease may be altered by administration of anticancer drugs. Since neoadjuvant chemotherapy with epirubicin and docetaxel is increasingly used in advanced breast cancer, our purpose was to assess the influence of this neoadjuvant chemotherapy on the expression of the growth factor receptor HER2/neu.
引用
收藏
页码：207 / 213
页数：6
相关论文
共 50 条
  • [41] Activity of combination chemotherapy, docetaxel and epirubicin as neoadjuvant therapy for women with breast cancer
    Tfayli, Arafat
    Holter, Jennifer
    Bova, Abby
    Venkatappa, Siddhartha
    Bullock, Susie
    Dooley, William
    Ozer, Howard
    ANTICANCER RESEARCH, 2006, 26 (6C) : 4911 - 4916
  • [42] COST-EFECTIVENESS ANALYSIS OF DOCETAXEL VS DOCETAXEL plus TRASTUZUMAB AS FIRST LINE THERAPY IN THE TREATMENT OF PATIENTS WITH METATSTASTIC BREAST CANCER HER2/NEU+
    Tenorio, C.
    Vargas, J.
    Martinez, J.
    Paladio, A.
    VALUE IN HEALTH, 2009, 12 (07) : A274 - A274
  • [43] HER2/NEU PROTEIN EXPRESSION IN COLORECTAL CANCER
    Andrews, Nimmy
    Letha, V
    Sankar, S.
    JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2019, 8 (06): : 341 - 345
  • [44] HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy
    Junker, K
    Stachetzki, U
    Rademacher, D
    Linder, A
    Macha, HN
    Heinecke, A
    Müller, KM
    Thomas, M
    LUNG CANCER, 2005, 48 (01) : 59 - 67
  • [45] Neoadjuvant biweekly dose-dense chemotherapy with fluouracil, epirubicin, and cyclophosphamide (FEC 90), followed by docetaxel in patients with HER2-neu negative primary breast cancer
    Rodriguez-Abreu, D.
    Murias, A.
    Garcia, M.
    Vega, V.
    Garcia, C.
    Mori, M.
    Baez-Acosta, B.
    Diez, A.
    Almenarez, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] CCN5 down regulates HER2/neu expression in HER2 positive breast cancer cells
    Sarkar, Sandipto
    Maity, Gargi
    Das, Amlan
    Majumder, Monami
    Banerjee, Snigdha
    Banerjee, Sushanta
    CANCER RESEARCH, 2015, 75
  • [47] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Zhang, Chao
    Suo, Aili
    Shi, Qiuying
    Wei, Zhimin
    Li, Zaibo
    Krishnamurti, Uma
    Li, Xiaoxian
    MODERN PATHOLOGY, 2019, 32
  • [48] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Meisel, Jane
    Suo, Aili
    Zhang, Chao
    Wei, Zhimin
    Aneja, Ritu
    Li, Zaibo
    Nahta, Rita
    Li, Xiaoxian
    MODERN PATHOLOGY, 2019, 32
  • [49] Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients
    Bo, Jiaqi
    Yu, Baohua
    Bi, Rui
    Xu, Xiaoli
    Cheng, Yufan
    Tu, Xi aoyu
    Bai, Qianming
    Yang, Wentao
    Shui, Ruohong
    CLINICAL BREAST CANCER, 2023, 23 (04) : 436 - 446
  • [50] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Zhang, Chao
    Suo, Aili
    Shi, Qiuying
    Wei, Zhimin
    Li, Zaibo
    Krishnamurti, Uma
    Li, Xiaoxian
    LABORATORY INVESTIGATION, 2019, 99
12345